Search Results

Ambry Genetics announced that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.

Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced their companies’ selection by the University of California, Irvine and the GREGoR Consortium to support the Pediatric Mendelian Genomics Research Center program to better understand the underlying biology of rare diseases.

Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., unveiled at the American Society of Human Genetics annual meeting results of a study published in JAMA Oncology that assessed the cumulative impact of paired DNA and RNA testing on detecting disease-causing germline genetic variants and resolution of variants of uncertain significance.

LifeStrands Genomics and Ambry Genetics have joined forces to provide clinical genetic testing services in Singapore.

Unilabs, a leading diagnostic services provider, and Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, have entered an exclusive partnership to enhance high-quality genetic testing services for government-sponsored and biopharma companies conducting international clinical trials and research.

3X4 Genetics, leader in the field of genetics-based health, announced a partnership with The Metabolic Terrain Institute of Health to serve as the innovative nonprofit’s genetics provider.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test.